Time filter

Source Type

Edmonton, Canada

Ceri H.,University of Calgary | Olson M.E.,Innovotech Inc. | Turner R.J.,University of Calgary
Expert Opinion on Pharmacotherapy | Year: 2010

While antibiotic resistance has grabbed the headlines and the attention of the pharmaceutical industry, the lack of susceptibility of biofilms formed both on animate and inanimate surfaces deserve greater attention from the industry, medical practitioners and regulators. The current literature tells us that the inherent tolerance to antibiotics demonstrated by antibiotic-sensitive organisms when grown as a biofilm clearly identifies a major disconnect between our current practices in antimicrobial development, diagnostics and efficacy in patient treatment. A paradigm shift is required in the way we utilize conventional antimicrobials and in the way we screen for next-generation antibiotics with efficacy to treat biofilms associated with chronic, recurrent and device related infections. This paradigm shift must not only take place in industry but also in how drugs are brought to the marketplace for acceptance. © 2010 Informa UK Ltd. Source

Rello J.,Rovira i Virgili University | Afessa B.,Rochester College | Anzueto A.,South Texas Veterans Health Care System | Arroliga A.C.,University of Texas Health Science Center at San Antonio | And 6 more authors.
Critical Care Medicine | Year: 2010

Objective: To elucidate the mechanism of action of the silver-coated endotracheal tube in models of the early pathogenesis of ventilator-associated pneumonia. Design: Open-labeled, prospective, controlled, sequentially conducted, preclinical studies, and in vitro assessment of tubes from patients. Setting: Microbiology laboratory of a device manufacturer, animal research facility of a university, and a tertiary medical center. Interventions: Endotracheal tubes were similar except for the silver coating. In the 21-day in vitro elution model, tube samples were incubated in saline solution at 37.8°C. In the in vitro adherence model, coated and uncoated tubes were exposed to 21 respiratory isolates of radiolabeled microorganisms for 2-4 hrs. In the animal model, 12 healthy white rabbits were intubated for 16 hrs with noncuffed silver-coated or uncoated tubes and challenged with buccal administration of Pseudomonas aeruginosa. In the in vitro assessment, tubes from 16 patients underwent quantitative culture assessment and qualitative confocal laser scanning microscopy. Measurements and Main Results: After in vitro incubation, the mean residual silver concentration was 2.6 μg/cm, confirming that the coating was not entirely depleted. In vitro adherence to the silver-coated endotracheal tube was less than that of the uncoated tube for 12 of 21 isolates and equivalent for seven. For example, adherence to the silver-coated endotracheal tube was reduced >90% for all five isolates of P. aeruginosa (p <.05). In rabbits, P. aeruginosa colonization on the silver-coated endotracheal tube was reduced 99.9% compared with that on the uncoated tube (p <.0001); colonization in the tracheal and lung tissue was reduced >99% (p <.05). In the in vitro assessment, pathogens were detected on none of nine silver-coated tubes from patients and three of seven control tubes (p >.05). Conclusions: The collective findings of this series of studies demonstrated that the silver-coated endotracheal tube was active in models designed to mimic the early pathogenesis of ventilator-associated pneumonia. © 2010 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins. Source

The present application discloses a method of making a surface antimicrobial by coating or forming a surface with a silver (I) periodate as well as articles of manufacture comprising a silver (I) periodate. The present application also discloses a method of preventing or reducing microbial contamination on a substrate by coating the substrate with at least one silver (I) periodate. The substrate can be a wound dressing, a medical instrument, a medical device, a metallic article, a plant or a seed.

Innovotech Inc. | Date: 2013-07-19

The present invention is silver (I) periodate compounds and their use in preventing or reducing microbial contamination. The invention includes gels, coatings, and articles of manufacture having a surface contacted or coated with a gel comprising an antimicrobial silver (I) compound. Methods of treatment are also disclosed.

Allan N.D.,Innovotech Inc. | Giare-Patel K.,Teleflex | Olson M.E.,Innovotech Inc. | Olson M.E.,University of Alberta
Journal of Biomedicine and Biotechnology | Year: 2012

Infection is the leading complication associated with intravascular devices, and these infections develop when a catheter becomes colonized by microorganisms. To combat this issue, medical device manufacturers seek to provide healthcare facilities with antimicrobial medical devices to prevent or reduce the colonization. In order to adequately evaluate these devices, an in vivo model is required to accurately assess the performance of the antimicrobial devices in a clinical setting. The model presented herein was designed to provide a simulation of the subcutaneous tunnel environment to evaluate the ability of an antimicrobial peripherally inserted central catheter (PICC), coated with chlorhexidine based technology, to reduce microbial migration and colonization compared to an uncoated PICC. Three samples of control, uncoated PICCs and three samples of coated PICCs were surgically tunneled into the backs of female New Zealand White rabbits. The insertion sites were then challenged with Staphylococcus aureus at the time of implantation. Animals were evaluated out to thirty days and sacrificed. Complete en bloc dissection and evaluation of the catheter and surrounding tissue demonstrated that the chlorhexidine coated catheter was able to significantly reduce microbial colonization and prevent microbial migration as compared to the standard, un-treated catheter. © 2012 Nicholas D. Allan et al. Source

Discover hidden collaborations